Background Current high lung cancer mortality rates are mainly due to the occurrence of metastases and therapeutic resistance. Therefore, simultaneous targeting of these processes may be a valid approach for the treatment of this type of cancer. Here, we assessed relationships between CXC chemokine receptor type 4 (CXCR4) and focal adhesion kinase (FAK) gene expression levels and expression levels of the drug resistance-related genes ABCB1 and ABCC1, and tested the potential of CXCR4 and FAK inhibitors to reverse doxorubicin (DOX) resistance and to decrease the invasive capacity of non-small cell lung carcinoma (NSCLC) cells. Methods qRT-PCR was used for gene expression analyses in primary lung tissue samples obtained from 30 NSCLC patients and the human NSCLC-derived cell lines NCI-H460, NCI-H460/R and COR-L23. MTT, flow cytometry, cell death and β-galactosidase activity assays were used to assess the in vitro impact of CXCR4 and FAK inhibitors on DOX sensitivity. In addition, invasion and gelatin degradation assays were used to assess the in vitro impact of the respective inhibitors on metastasis-related processes in combination with DOX treatment. Results We found that ABCB1 over-expression was significantly associated with CXCR4 and FAK over-expression, whereas ABCC1 over-expression was associated with increased FAK expression. We also found that CXCR4 and FAK inhibitors strongly synergized with DOX in reducing cell viability, arresting the cell cycle in the S or G 2 /M phases and inducing senescence. Additionally, we found that DOX enhanced the anti-invasive potential of CXCR4 and FAK inhibitors by reducing gelatin degradation and invasion. Conclusions From our data we conclude that targeting of CXCR4 and FAK may overcome ABCB1 and ABCC1-dependent DOX resistance in NSCLC cells and that simultaneous treatment of these cells with DOX may potentiate the anti-invasive effects of CXCR4 and FAK inhibitors.
Introduction
Lung cancer is the most frequent cause of cancer-related death worldwide. Even though chemotherapy is currently the primary approach for lung cancer treatment, it fails to eliminate all cancer cells [1, 2] . The major causes of treatment failure are the development of metastasis and chemotherapy resistance. At the earliest stage of lung cancer, a substantial percentage of the patients already carries micro-metastases [3] . Patients with (micro)metastases may exhibit increased serum free-DNA levels that significantly correlate with the response to therapy [4] . Intrinsic chemotherapy resistance is a pre-existing resistance that leads to initial drug treatment failure, while acquired chemotherapy resistance develops during treatment. Overexpression of ATP-binding cassette (ABC) transporters, such as ABCB1/MDR1/P-gp and ABCC1/MRP1, is one of the most common and extensively studied causes of chemotherapy resistance [5, 6] . Understanding the mechanisms of lung cancer metastasis and therapy resistance, as well as the development of new treatment strategies, appears extremely important for improving the prognosis of lung cancer. This is particularly true for non-small cell lung cancer (NSCLC), which is the most common form of lung cancer.
A novel and promising approach for the treatment of lung cancer that is aimed at reducing invasion and therapy resistance is the targeting of the CXC chemokine receptor type 4 (CXCR4) [7] . CXCR4 is a G protein-coupled receptor for stromal cell-derived factor 1 (SDF-1), which is expressed in most cancers, including NSCLC [8, 9] . A high expression of CXCR4 has been found to be related to the invasion and migration in NSCLC cells [9] . Additional studies have advocated that the expression and activation of CXCR4 in lung cancer cells is associated with an increased resistance to both chemotherapy and radiotherapy [10] . CXCR4 is involved in activation of the phosphoinositide 3-kinase (PI-3 K)/AKT signaling pathway and its downstream phosphorylation of focal adhesion kinase (FAK) [11] . FAK is a cytoplasmic proteintyrosine kinase and one of the central players in integrin and growth factor receptor-mediated signaling. It has been shown that FAK signaling controls the movement, invasion and metastasis of NSCLC cells [12] and is also associated with the acquisition of chemotherapy resistance in this type of cancer [13] .
Together, these data suggest that targeting CXCR4 and/or FAK may alter key pathologic processes involved in NSCLC progression and its response to therapy. Therefore, we set out to assess associations between CXCR4 and FAK gene expression levels and those of the ABC transporter genes ABCB1 and ABCC1 in patient-derived NSCLC samples. Next, we examined the potential of CXCR4 and FAK inhibitors (WZ811 and PF-573228, respectively) in reversing resistance to a clinically used cytotoxic drug, doxorubicin (DOX), in the NSCLC-derived cell lines NCI-H60/R and COR-L23. We also tested the ability of the CXCR4 and FAK inhibitors, in addition to DOX treatment, to suppress the migratory and invasive capacities of NSCLC-derived cells. Our data provide a rationale for the use of CXCR4 and FAK antagonists as an approach to circumvent DOX resistance and to prevent metastasis formation in NSCLC.
Materials and methods

Tissue samples
Paired tumor and adjacent normal lung tissue samples from 30 NSCLC patients who underwent surgery at the Clinic for Thoracic Surgery (Belgrade, Serbia) were included in this study. The samples were stored in liquid nitrogen until DNA and RNA extraction. The samples were collected after obtaining informed consent and approval from the Ethics Committee, in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. The diagnosis NSCLC, as well as the histological grade, stage, necrosis and lymph node invasion status were established through histological analyses of the surgical specimens. All specimens were subjected to an earlier analysis and their clinicopathological parameters were reported before [14] . Neither presurgical chemotherapy nor radiotherapy were administered.
Cells and culture conditions
The NCI-H460 and COR-L23 NSCLC-derived cell lines were purchased from the American Type Culture Collection (ATCC, Rockville, MD) and the European Collection of Cell Cultures (ECACC, Salisbury, UK), respectively. Doxorubicin resistant NCI-H460/R cells were selected from NCI-H460 cells and cultured in a medium containing 100 nM doxorubicin [15] . All cells were maintained at 37°C in a humidified 5 % CO2 atmosphere in RPMI-1640 medium supplemented with 10 % fetal bovine serum (FBS), 2 mM L-glutamine, 4.5 g/l glucose, 10,000 U/ml penicillin, 10 mg/ml streptomycin and 25 μg/ml amphotericin B solution. The cells were sub-cultured at 72 h intervals using 0.25 % trypsin/ EDTA, and seeded into fresh medium at the following densities: 8000 NCI-H460 cells/cm 2 , 16,000 NCI-H460/R cells/ cm 2 and 8000 COR-L23 cells/cm 2 .
Drugs
Cisplatin (CPt) was obtained from Pfizer (Perth Pty Ltd., Bentley, Australia), doxorubicin (DOX) from EBEWE (Arzneimittel GmbH, Vienna, Austria), paclitaxel (PTX) from Sigma-Aldrich Chemie Gmbh (Taufkirchen, Germany), and the CXCR4 antagonist WZ811 and the FAK inhibitor PF-573228 from Selleckchem (Houston, Texas, USA). CPt and DOX were diluted in sterile water, and 1 mM aliquots were stored at room temperature and 4°C, respectively. PTX was diluted in absolute ethanol and 1 mM aliquots were stored at −80°C. WZ811 and PF-573228 were disolved in DMSO (Sigma-Aldrich Chemie Gmbh, Germany) to 10 mM stocks and stored at −20°C. Before treatment, all drugs were freshly diluted in sterile water.
MTT assay and median effect analysis
Cell viability was assessed by the MTT assay (SigmaAldrich). For this assay, cells grown in 25 cm 2 tissue flasks were trypsinized, seeded into flat bottomed 96-well tissue culture plates (1000 cells/well for the NCI-H460, NCI-H460/R and COR-L23 cell lines), and incubated overnight in 100 ml of the appropriate medium. After 24 h, the cells were treated with PF-573228 (1-50 μM), WZ811 (1-50 μM), PTX (0.001-1 μM), DOX (0.001-10 μM) and Cpt (0.5-25 μM), and incubated for 72 h. The combined effects of PF-573228 and WZ811 with DOX on viability after 72 h were studied in NCI-H460/R and COR-L23 cells. For the simultaneous treatment of NCI-H460/R cells, 3 different concentrations of PF-573228 (2.5, 5 and 7.5 μM) and WZ811 (5, 10 and 25 μM) were combined with DOX (0.5-7.5 μM). Similarly, COR-L23 cells were treated with 3 different concentrations of PF-573228 (2.5, 5 and 7.5 μM) and WZ811 (2.5, 5 and 10 μM) in combination with DOX (10-500 nM). The cytotoxicity of PF-573228 (2.5 μM) and WZ811 (10 μM) in combination with DOX (0.5-7.5 μM) on NCI-H460/R cells, and PF-573228 (5 μM) and WZ811 (10 μM) in combination with DOX (10-500 nM) was also evaluated after 24 h. Additionally, both inhibitors were simultaneously combined with DOX to examine their cytotoxicity. Specifically, PF-573228 (2.5 μM) and WZ811 (10 μM) were combined with DOX (0.5-7.5 μM) on NCI-H460/R cells, while PF-573228 (5 μM) and WZ811 (10 μM) were combined with DOX (10-500 nM) on COR-L23 cells for 72 h. After incubation, 100 μl MTT solution (1 mg/ml) (Sigma-Aldrich Chemie Gmbh, Germany) was added to each well after which the plates were incubated at 37°C for 4 h. The resulting formazan product was dissolved in 200 μl dimethyl sulfoxide and its absorbance was measured at 540 nm using an automatic microplate reader (LKB 5060-006 Micro Plate Reader). All cytotoxicity tests were performed in triplicate and repeated at least three times. The results are presented as the mean value with standard error.
The half maximal inhibitory concentration (IC 50 ) was calculated for each drug. To examine the nature of the interactions between the inhibitors (PF-573228 and WZ811) and DOX, the data were analyzed using the CalcuSyn software tool (Biosoft, Cambridge, UK), that employs the combination index (CI) method of Chou and Talalay [16] . A CI value between 0.9 and 1.1 indicates an additive effect, whereas a CI value < 0.9 indicates synergy and a CI value > 1.1 indicates antagonism.
Based on the data obtained, we used drug doses with the most pronounced synergistic effect on cell viability in the further experiments. The concentrations used for single and combined treatments were as follows: a) PF-573228 2.5 μM, WZ811 10 μM and DOX 1 μM for NCI-H460/R cells and b) PF-573228 5 μM, WZ811 10 μM and DOX 50 nM for COR-L23 cells.
RNA extraction and RT-PCR
Total RNA was extracted from tumor and corresponding normal tissues samples of all 30 NSCLC patients, as well as from the NCCLC-derived NCI-H460, NCI-H460/R and COR-L23 cells, and cells treated with DOX for 72 h. The extractions were carried out using Trizol® reagent (Invitrogen Life Technologies, USA) according to the manufacturer's instructions. The respective RNAs were quantified by spectrophotometry and their quality was determined by agarose gel electrophoresis. RT reactions were performed using 2 μg total RNA and a High-capacity cDNA reverse transcription kit (Applied Biosystems, USA) according to the manufacturer's instructions.
Quantitative real-time PCR
Quantitative real time PCR (qRT-PCR) was used to assess differences in FAK, CXCR4, ABCB1 and ABCC1 gene expression levels in tumor samples relative to matched normal patient samples. qRT-PCR was also applied to assess ABCB1 and ABCC1 gene expression levels in NCI-H460/R and COR-L23 cells compared to NCI-H460 cells. Finally, alterations in CXCR4 gene expression were evaluated in NCI-H460, NCI-H460/R and COR-L23 cells upon 20 nM, 1 μM and 50 nM DOX treatment, respectively. The reactions were performed using a Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific, USA) on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, USA) according to the manufacturer's recommendations, using 100 ng cDNA in conjunction with primers specific for each gene and ACTB as internal control for normalization [17] [18] [19] [20] [21] . Each sample was tested in triplicate and relative gene expression levels were analyzed by the 2 −ΔΔCt method [22] .
Western blot analysis
Proteins were isolated in RIPA buffer containing a complete protease inhibitor cocktail and a phosphatase inhibitor cocktail (PhosSTOP; Roche, Mannheim, Germany). The homogenates were centrifuged at 14,000 rpm for 30 min at 4°C after which the protein concentrations in the supernatants were determined using a Micro BCA Protein Assay Kit (Pierce Biotechnology, USA). Thirty μg protein per lane were separated by 10 % SDS-PAGE for Western blot analysis [23] . After electrophoresis, the proteins were transferred onto PVDF membranes, which were blocked in 1 % bovine serum albumin in Trisbuffered saline/0.1 % Tween-20 (TBST) for 1 h at room temperature and incubated overnight at 4°C with the following primary rabbit antibodies: anti-AKT (1:1000; Santa Cruz, sc-8312), anti-pAKT (1:750; Santa Cruz, sc-7985), anti-ERK (1:1000; Santa Cruz, sc-94), anti-pERK (1:1000; Santa Cruz, sc-16,982), anti-FAK (1:1000; Invitrogen, 701,094) and anti-pFAK (pY397) (1:1000; Invitrogen, 44-625G). After several rinses in TBST, the membranes were incubated for 1 h/RT with a Horse Radish Peroxidase (HRP)-conjugated bovine anti-rabbit secondary antibody (1:5000; Santa Cruz, sc-2370). HRP-immunoreactive bands were visualized by enhanced chemiluminiscence (ECL, GE Healthcare) and exposed to film (Kodak Biomax). Each blot was re-probed with a primary mouse β-actin antibody (1:5000; Santa Cruz, sc-8432) and incubated with an anti-mouse secondary antibody
(1:5000; Dako, 2021-02). All antibodies were diluted in TBST. Signals were quantified by densitometry using Image Quant software (v. 5.2, GE Healthcare) and expressed as relative values (i.e., density ratio normalized to the corresponding β-actin signal).
Cell cycle analysis
Differences in cell cycle kinetics after treatment with PF-573228, WZ811 and DOX, either separately or in various combinations, were assessed by flow cytometry using propidium iodide (PI) staining [24] . Unsynchronized cells were seeded in 6-well plates at densities of 100,000 cells/ well for each cell line. The attached and floating cells were trypsinized, collected by centrifugation and fixed in 70 % ethanol for 24 h at −20°C. Next, the cells were re-suspended in 500 μl phosphate buffered saline (PBS), pretreated with 50 μg/ml RNAse A at 37°C for 30 min and incubated with 20 μg/ml propidium iodide for at least five minutes before flow cytometric analysis. The analyses were performed on a FACSClibur flow cytometer (Becton Dickinson, Oxford, United Kingdom). A minimum of 10,000 events was collected for each experimental sample. The cell cycle distributions were determined automatically in Mod-FIT (Verity Software House, Inc., USA). Independent experiments were performed at least three times.
Cell death analysis
The percentages of apoptotic, necrotic and viable cells were determined after Annexin-V-FITC (AV) and PI staining. NCI-H460/R and COR-L23 cells were seeded in 6-well plates at a density of 100,000 cells/well and incubated overnight. After 72 h treatment, the attached and floating cells were collected by centrifugation after which the cell pellet was re-suspended in 100 μl binding buffer containing 10 mM HEPES/NaOH, 140 mM NaCl, 5 mM CaCl 2 (pH 7.4), supplemented with 0.2 μg AV and 0.2 μg PI. After incubation for 30 min at 37°C in the dark, an additional 400 ml binding buffer was added and the AV/PI staining patterns were analyzed by flow cytometry within 1 h. The fluorescence intensities were measured in a green FL1-H and a red FL2-H channel on a CyFlow Space flow cytometer (Partec, Münster, Germany). In each sample 10,000 cells were recorded, and the percentages of viable (AV-PI-), early apoptotic (AV+ PI-), late apoptotic (AV+ PI+) and necrotic (AV-PI+) cells were analyzed using the CellQuest Pro data analysis software tool.
β-galactosidase activity assay
The β-galactosidase activity of senescent cells was measured by flow cytometry using fluorescein-di-β-D-galacto-pyranoside (FDG, Thermo Fisher Scientific, USA) as substrate. After incubation at 37°C for 1 min 1 ml ice-cold PBS was added to the cells and they were stored on ice until FACS analysis on a CyFlow Space flow cytometer (Partec, Münster, Germany). Dead cells were excluded from the analysis based on uptake of 0.2 μg PI after the addition of FDG. For each sample, 10,000 cells were recorded and independent experiments were performed at least three times.
Gelatin degradation assay
NCI-H460/R and COR-L23 cells were seeded in 6-well plates with glass coverslips coated with AlexaFluor488 labeled gelatin (Gelatin From Pig Skin, Oregon Green® 488 Conjugate, Life Technologies, USA) at a density of 50,000 cells/well. The cells were treated with the above described concentrations of PF-573228, WZ811 and DOX, separately and in various combinations. After 24 h, the cells were fixed with 4 % paraformaldehyde and, after washing in PBS, stained with Hoechst 33342 (Sigma-Aldrich Chemie Gmbh, Germany) for 15 min at room temperature and ActinRed 555 (Life Technologies, USA) for 1 h at room temperature. Next, cells and degradation areas were analyzed at 20× magnification under a Zeiss Axiovert inverted fluorescent microscope (Carl Zeiss Foundation, Germany) equipped with AxioVision 4.8 Software. The volume of the dark areas caused by degradation of gelatin was measured using ImageJ software and normalized to the volume of the cell. At least 100 cells were analyzed per experiment. All experiments were performed at least three times.
Invasion assays
To quantitatively evaluate the effect of PF-573228, WZ811 and DOX on the invasion potential of NCI-H460/R and COR-L23 cells, we used Transwell inserts (membrane pore size, 8 μm; diameter, 6.4 mm; BD Biosciences Discovery Labware) assembled in 24-well plates. 200,000 cells were seeded in serum free medium in the upper chambers covered with a layer of Matrigel Basement Membrane Matrix (BD Biosciences) (500 g/ml) and treated for 24 h with PF-573228, WZ811 and DOX, separately or in various combinations. The lower chambers were filled with RPMI-1640 medium supplemented with 10 % FBS as chemoattractant. A control of spontaneous cell invasion without 10 % FBS was included. After the incubation, cells that had invaded though the matrigel and its underlying membrane were fixed in 4 % paraformaldehyde-PBS and stained with Hoechst 33342. The cells that failed to invade remained on the upper surface and were carefully removed with a cotton swab, whereas the cells on the lower surface of the membranes were counted under a Zeiss Axiovert inverted fluorescent microscope at a 10× magnification. The average number of cells in 30 independent fields per membrane was analyzed. At least three independent experiments were performed. Results are presented as percentage of cells that invaded through the matrigel-coated membrane compared to the untreated control.
Statistical analyses
Statistical analyses were performed using STATISTICA 10.0. software (StatSoft, Inc., Tulsa, USA. 
Results
Increased expression of the FAK, CXCR4, ABCB1
and ABCC1 genes in primary NSCLC samples
Relative expression levels of the FAK, CXCR4, ABCB1 and ABCC1 genes in primary NSCLC samples were assessed by qRT-PCR. We found that, compared to the respective normal lung cancer samples, FAK was over-expressed in 47 % of the tumor samples, while an increased expression of CXCR4 was detected in 33 % of the tumor samples. The incidence of ABCB1 over-expression in the tumor samples was 17 %, while an increased ABCC1 expression level was observed in 37 % of the tumor samples. Overall, only FAK expression was significantly higher in the NSCLC tumor samples (p = 2.99e
) compared to its matched normal lung tissue samples (Fig. 1). 3.2 Positive associations between CXCR4, FAK, ABCB1 and ABCC1 gene expression levels Using statistical analyses, we found a significant association between over-expression of the ABCB1 and CXCR4 genes ( Table 1 , p = 0.002), as also between over-expression of the ABCB1 and FAK genes ( Table 1 , p = 0.01). Specifically, we found that the ABCB1 gene was over-expressed exclusively in cases with increased CXCR4 and FAK mRNA levels. Similarly, we found a statistically significant over-expression of both the ABCC1 and FAK genes ( Table 1 , p = 0.007), i.e., the frequency of ABCC1 over-expression was significantly higher in tumors with an increased FAK expression than in samples without a FAK over-expression (81.8 % versus 18.2 %).
NSCLC-derived cell lines NCI-H460/R and COR-L23 exhibit DOX resistance
The sensitivity to classical chemotherapeutics (DOX, PTX and CPt) was evaluated using a MTT assay in the NSCLCderived NCI-H460, NCI-H460/R and COR-L23 cell lines. By doing so, we found that both the NCI-H460/R and COR-L23 cell lines showed a resistance to DOX compared to the DOX response in NCI-H460 cells. The respective IC 50 values are listed in Table 2 . Fig. 2a ; p < 0.0001), whereas no changes were observed in the ABCC1 gene expression level compared to NCI-H460 cells. On the contrary, we found that COR-L23 cells exhibited a 4.5-fold higher expression level of the ABCC1 gene ( Fig. 2a ; p = 0.006), and a 10-fold decreased ABCB1 gene expression level compared to NCI-H460 cells ( Fig. 2a ; p = 0.0007).
CXCR4 gene expression is up-regulated in DOX-treated NCI-H460/R and COR-L23 cells
Next, we investigated alterations in CXCR4 gene expression levels after DOX treatment in NSCLC-derived cells. We found that NCI-H460/R and COR-L23 cells treated with DOX exhibited significantly higher CXCR4 expression levels compared to untreated controls, i.e., 6.6-fold (p = 0.008) and 3.6-fold (p = 0.01), respectively (Fig. 2b ).
DOX sensitivity is enhanced after combined PF-573228 or WZ811 treatment
To evaluate the effects of FAK and CXCR4 antagonists in overcoming DOX resistance, we first examined their cytotoxicity. By doing so, we found that treatment with increasing concentrations of PF-573228 (FAK inhibitor) and WZ811 (CXCR4 inhibitor) caused dose-dependent decreases in the viability of NCI-H460/R and COR-L23 cells, with low to moderate effects at concentrations up to 10 μM (Fig. 3a) . Next, we investigated the potential of PF-573228 and WZ811 to sensitize NCI-H460/R and COR-L23 cells to DOX in combined and simultaneous treatment regimens. We found that combined treatment with PF-573228 or WZ811 enhanced the DOX efficacy in both cell lines (Fig. 3b) . In addition we found that simultaneous applications of PF-573228, WZ811 and DOX did not further enhance the DOX efficacy compared to DOX treatment combined with each individual inhibitor (Online Resource 1). DOX in combination with each inhibitor exhibited mainly synergistic effects on growth inhibition of the DOX resistant cell lines (Fig. 3c) . Cotreatments with the most pronounced synergistic effects in NCI-H460/R (DOX 1 μM with PF-573228 2.5 μM or WZ811 10 μM) and COR-L23 (DOX 50 nM with PF-573228 5 μM or WZ811 10 μM) cells were applied in the following experiments.
3.7 PF-573228 and WZ811 induce decreased pFAK and pAKT protein levels in NCI-H460/R and COR-L23 cells First, we compared the expression levels of the pAKT, pERK and pFAK proteins between the NCI-H460/R and COR-L23 cells using Western blotting. We found that COR-L23 cells exhibited a 4.8-fold increased expression of pAKT (p = 0.02) and 2.9-fold increased expression of pFAK (p = 0.02) compared to NCI-H460/R cells, whereas the pERK level was found to be the same in both cell lines (Fig. 4a) . In order to next confirm CXCR4 and FAK inactivation by application of its corresponding inhibitors, we evaluated the pFAK and pAKT levels as measures of PF-573228 activity, as well as the pAKT and pERK levels as measures of CXCR4 inactivation by WZ811 (Fig. 4b) . We found that treatment with PF-573228, as well as its co-treatment with DOX, significantly decreased the level of pFAK, as also that of pAKT, compared to untreated controls in both cell lines. Specifically, we found that the pFAK and 
Combined treatments cause cell cycle redistribution in NCI-H460/R and COR-L23 cells
In order to examine the mechanism underlying the pronounced synergistic effects observed above, we decided to analyze the corresponding cell cycle kinetics. In doing so, we found that DOX treatment in both cell lines resulted in G 2 /M phase arrest, while the subsequent addition of PF-573228 or WZ811 led to further changes in cell cycle distribution (Fig. 5) . Specifically, we found that the addition of PF-573228, as well as WZ811, to DOX in NCI-H460/R cells completely disturbed its cell cycle distribution and caused an increase in the number of cells in the S phase (19 %) compared to their number in control samples (9 %) and samples treated with DOX (7 %). On the other hand, we found that a combined treatment with PF-573228 in COR-L23 cells had a more pronounced effect on G 2 /M phase arrest compared 
Effects of combined treatments on cell death induction in NCI-H460/R and COR-L23 cells
To assess whether the above observed perturbations in cell cycle distribution are accompanied by cell death, NCI-H460/R and COR-L23 cells untreated or treated with DOX, PF-573228 and WZ811, alone or in various combinations, were subjected to Annexin-V-FITC/PI staining. Subsequent flow cytometry analysis revealed a cell death inducing activity of DOX, DOX with PF-573228, as well as DOX with WZ811, in both cell lines (Fig. 6a) . These respective treatment regimens in NCI-H460/R cells significantly increased the percentage of necrotic cells compared to untreated cells by 32 %, 34 % and 27 %, respectively. Similarly, we found that necrosis was significantly induced upon the respective treatment regimens in COR-L23 cells by 13 %, 16 % and 14 %, respectively. In addition, we found that the combined treatment regimens in both cell lines did not cause a significant increase in necrosis compared to DOX treatment alone, suggesting that all the effects of drug combinations on cell death may be attributed to DOX only.
Combined treatment regimens induce senescence in DOX resistant NCI-H460/R and COR-L23 cells
To subsequently test the potential of the different treatment regimens to induce senescence in NCI-H460/R and COR-L23 cells, we measured β-galactosidase activities by flow cytometry using FDG as a fluorogenic substrate. Through this assay we found that DOX treatment as well as combined DOX with PF-573228 and DOX with WZ811 treatments, led to significant increases in the percentages of FDG positive NCI-H460/R cells compared to untreated cells by 13 %, 32 % and 39 %, respectively (Fig. 6b) . The additive effects of the combined treatment regimens were also significant compared to the effects of each single compound. In addition, we found that co-treatment of COR-L23 cells with DOX and PF-573228 or with DOX and WZ811 led to significant increases in the percentages of FDG positive cells compared to untreated cells by 45 % and 27 %, respectively, as well as to DOX treatment alone. The effect of the DOX-PF-573228 combination on inducing senescence was the same as that of PF-573228 alone, while the effect of the DOX-WZ811 combination had a significantly more pronounced effect than the inhibitor alone.
Combined treatment regimens decrease the capacity of NCI-H460/R and COR-L23 cells to degrade gelatin
Gelatin degradation assays were performed to test the ability of resistant NSCLC cells to degrade the extracellular matrix. We found that NCI-H460/R cells significantly less efficiently degraded gelatin after treatment with PF-573228, as well as the combination of DOX with PF-573228 and DOX with WZ811. Specifically, we found that the combined treatment regimens caused 3-fold decreases in degradation areas compared to those in untreated control cells ( Fig. 7a ; p < 0.0001) and were more efficient in suppressing this degradation compared to single inhibitor treatment regimens (p < 0.0001). Similarly, we found that co-treatment of COR-L23 cells with DOX and PF-573228, as well as with DOX and WZ811, resulted in 3-fold and 2-fold decreases in gelatin degradation, respectively, compared to untreated control cells ( Fig. 7a ; p < 0.0001). Importantly, we noted that the suppression of gelatin degradation after cotreatment was significantly higher than that after single inhibitor treatment (p < 0.005).
Co-treatment regimens lead to invasion suppression of NCI-H460/R and COR-L23 cells
An invasion assay was used to determine the ability of NSCLC-derived cells to pass through matrigel and an underlying membrane. The assay was performed after 24 h (Fig. 7b) . Importantly, we noted that only 24 % of COR-L23 cells passed through Matrigel after a combined DOX-PF-573228 treatment compared to 100 % in case of untreated cells ( Fig. 7b ; p = 0.005). This drug combination also significantly reduced the invasive capacity of these cells compared to DOX-only and PF-573228-only treatment by 42 % (p = 0.01) and 20 %, (p = 0.02), respectively.
Discussion
Despite the major impact of metastasis formation and drug resistance on therapy response, their interrelationships and mutual contributions have not been thoroughly investigated, and their simultaneous targeting has just recently become into focus. In the present study, we examined possible associations between genes involved in tumor invasion and migration and genes related to drug resistance in NSCLC patients, i.e., between the expression of the CXCR4 and FAK genes involved in cell migration and invasion and the expression of the drug resistance-associated genes ABCB1 and ABCC1. Overall, we found that the mRNA expression levels of the individual genes examined were in accordance with those reported in the literature [25] [26] [27] [28] [29] [30] . In addition, we found that overexpression of the CXCR4 and FAK genes was directly associated with increased expression of the ABCB1 and ABCC1 genes, i.e., FAK expression was significantly associated with both ABCB1 and ABCC1 expression and CXCR4 expression was only significantly associated with ABCB1 expression. These links between mRNA expression levels suggest that associations between metastatic and drug-resistance processes may at least in part be transcriptionally regulated [31] . An effective strategy in chemotherapeutic cancer treatment is the combination of multiple drugs with different modes of action. This strategy has significantly contributed to overcoming drug resistance and to reducing adverse side effects through decreasing the dose of individual drugs based on their synergistic actions. Currently, there is a trend towards the synthesis of agents that target specific molecular alterations in tumors [32] , and the effects of targeting either cell surface receptors or intracellular signaling molecules in combination with conventional chemotherapies have already extensively been evaluated in various NSCLC clinical trials [33] . Based on this information and our current results, we hypothesized that targeting of CXCR4 or FAK may, besides affecting tumor invasion and migration, serve as an efficient approach to overcome drug resistance.
To test this hypothesis, we used three NSCLC-derived cell lines, NCI-H460, NCI-H460/R and COR-L23, of which the latter two exhibit substantial levels of DOX resistance compared to the first one. The NCI-H460/R cell line, which was derived from the NCI-H460 cell line after continuous exposure to DOX, exhibits a classical acquired multidrug resistant phenotype, with marked cross resistance to DOX and PTX as a consequence of ABCB1 gene over-expression [15] . The COR-L23 cell line exhibits resistance to only DOX, which is an intrinsic resistance since this cell line was not exposed to drugs before (http://www.phe-culturecollections.org.uk/). This latter cell line exhibits a high level of ABCC1 gene expression. We used the NCI-H460/R and COR-L23 cells as a model system to study both acquired (ABCB1-dependent) and intrinsic (ABCC1-dependent) NSCLC DOX resistance reversal. We found that DOX treatment led to a significant increase in the expression of the CXCR4 gene in both resistant cell lines. This implies an important role of CXCR4 in the response to DOX in our model system, as has similarly been shown by Dessein et al. who reported that DOX resistant colon cancer-derived cells exhibited increased CXCR4 mRNA and protein levels [34] . This result prompted us to restore the sensitivity to DOX treatment in NSCLC cells by blocking CXCR4 and its downstream target FAK using specific antagonists. We found that the application of DOX in combination with CXCR4 or FAK antagonists resulted in profound synergistic effects on growth inhibition of NCI-H460/R and COR-L23 cells compared to individual treatments. The CXCR4 and FAK inhibitors successfully sensitized both resistant cell lines to DOX and decreased the concentration necessary to achieve the desired cytotoxic effect. Recently, different CXCR4 inhibitors were successfully combined with DOX in melanoma and lung cancer cells to reduce their growth and to suppress their metastatic capacity [35, 36] . The role of CXCR4 inhibitors in overcoming DOX resistance has, however, not previously been examined, although the CXCL12/CXCR4 axis has been shown to confer resistance to DOX in leukemic cells [37] . Several investigators have efficiently exploited different strategies to suppress FAK activity and, by doing so, have been able to sensitize breast carcinoma, neuroblastoma and HeLa cells to DOX [38] [39] [40] . Interestingly, Datta et al. were able to abolish DOX resistance in MCF-7 breast cancer cells through synthetic FAK targeting and flavone treatment [41] .
We found that simultaneous application of both CXCR4 and FAK inhibitors in combination with DOX treatment did not additionally reduce the cell viability compared to DOX treatment in combination with each single inhibitor. These results suggest that the two tested inhibitors act through the same signaling pathway. This assumption was subsequently confirmed by Western blot analysis, i.e., the FAK inhibitor PF-573228 efficiently decreased the level of pFAK as well as its downstream target pAKT in both resistant cell lines. In addition, we found that the effects of the CXCR4 antagonist WZ811 were mediated through decreasing the levels of the same molecules, pAKT in NCI-H460/R cells and pFAK in COR-L23 cells. Interestingly, significant inhibitory effects of WZ811 were achieved in both cell lines only when combined with DOX, probably due to the increased level of its target, CXCR4, in response to DOX. Earlier reports have indicated that abrogation of CXCR4 and FAK activity in addition to DOX treatment may cause apoptosis [42, 43] . Although we did not observe any significant changes on the cell death level, we found that combined treatments with the inhibitors and DOX caused S and G 2 /M phase cell cycle arrest in NCI-H460/R and COR-L23 cells, respectively. In addition, we found that the co-treatments resulted in increased senescenceassociated β-galactosidase activities, which was previously shown to be associated with DOX treatment [44] and FAK silencing [45] . These cell cycle perturbations and senescence inductions may represent mechanisms through which CXCR4 and FAK antagonists, in conjunction with DOX, synergistically decrease NSCLC cell viability. Interestingly, we found that the two DOX resistant cell lines responded differentially to the co-treatments, i.e., the FAK inhibitor was more efficient in blocking the cell cycle and inducing senescence in COR-L23 cells and the CXCR4 inhibitor was more potent in inducing senescence in NCI-H460/R cells.
Besides its frequent resistance to chemotherapy, lung cancer is also extremely invasive. Alterations in CXCR4 and FAK expression are known to enhance the invasive and metastatic potentials of lung cancer [7, 46] . Xie et al. successfully showed that CXCR4 silencing resulted in a decreased metastatic potential of NSCLC cells [47] , and Singla et al. recently reported anti-metastatic effects of a CXCR4 inhibitor in a murine model of metastatic human NSCLC [48] . To the best of our knowledge, the anti-invasive effects of FAK inhibition have not previously been examined in lung cancer. Here, we show that DOX can significantly potentiate the anti-invasive effects of CXCR4 and FAK inhibitors in DOX resistant NSCLC cell lines. Both combined treatments were almost equally efficient in inhibiting the capacity of NCI-H460/R and COR-L23 cells to degrade gelatin. A subsequent invasion assay, which sublimates the cell's ability to degrade matrigel as well as to migrate, revealed that a combined DOX and FAK inhibitor treatment was most effective in COR-L23 cells, while a combined DOX and CXCR4 inhibitor treatment was most effective in NCI-H460/R cells.
We speculate that the differences observed in migratory responses, as well as in cell cycle distribution and senescence induction of the two DOX resistant cell lines upon cotreatment may at least partially be attributed to the inherent differences in pFAK levels in these cell lines, as revealed by Western blot analysis, causing COR-L23 cells to be more responsive to the FAK inhibitor. In analogy, the more pronounced induction of CXCR4 expression upon DOX treatment in NCI-H460/R cells may explain the better response of these cells to the CXCR4 antagonist. An explanation for the different responses of the NCI-H460/R and COR-L23 cells may be found in the positive correlations observed between CXCR4 and ABCB1 as well as FAK and ABCC1 overexpression in the primary patient samples. Since NCI-H460/R cells show a high expression of ABCB1 and COR-L23 cells show a high expression of ABCC1, we assume that inhibition of CXCR4 more efficiently synergizes with DOX in NCI-H460/R cells and that FAK inhibition more efficiently synergizes with DOX in COR-L23 cells.
In conclusion, we show for the first time an association between genes involved in metastasis and drug resistance in human NSCLC cells. Our results additionally indicate that inhibition of CXCR4 and FAK in combination with DOX treatment may be used to sensitize DOX resistant NSCLC cells to this clinically used chemotherapeutic drug. Such treatment regimens may also be used to overcome acquired or intrinsic DOX resistance, as well as ABCB1 or ABCC1 dependent resistance. These co-treatment regimens may also be beneficial in suppressing the invasive and migratory potentials of DOX resistant NSCLC cells. A further elucidation of the mechanisms through which the metastatic and drug resistance pathways associate may lead to the development of more effective targeted therapeutic strategies.
